Evaluation of postmenopausal bleeding
Any vaginal bleeding occurring one year or more after the final menstrual period must be evaluated with transvaginal ultrasound and endometrial biopsy, followed by hysterectomy for confirmed cancer or progestin therapy for hyperplasia, to exclude endometrial cancer even though atrophy is the most common eventual cause.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
Postmenopausal bleeding is any vaginal bleeding occurring 12 months or more after the final menstrual period and is always abnormal, a presenting sign that requires a directed workup, not a diagnosis.
- Epidemiology
Postmenopausal bleeding affects roughly 5% to 10% of postmenopausal women and is one of the most common gynecologic complaints prompting referral in this age group.
- Risk factors
Unopposed estrogen exposure is the dominant risk factor: obesity (peripheral aromatization of androgens to estrogen in adipose tissue), nulliparity, early menarche, late menopause, and chronic anovulation such as polycystic ovary syndrome.
- Pathophysiology
Unopposed estrogen drives endometrial glandular proliferation without the stabilizing effect of progesterone, leading first to hyperplasia and, with accumulating cytologic atypia, to endometrioid (type I) adenocarcinoma.
- Clinical features
The presenting sign is vaginal bleeding, spotting, or blood-tinged discharge occurring at least 12 months after the last menstrual period, ranging from scant spotting to heavy flow; amount and…
- Differential diagnosis
Endometrial carcinoma: the diagnosis that must be excluded first; thickened or irregular endometrial stripe on ultrasound, confirmed by biopsy showing neoplastic glandular proliferation.
- Diagnosis
Endometrial biopsy is the confirmatory test for postmenopausal bleeding and establishes the diagnosis by histology; it can be obtained first-line or after ultrasound, since biopsy is usually performed regardless of the ultrasound findings.
- Management
First, confirm the bleeding source is uterine on pelvic exam and obtain transvaginal ultrasound or proceed directly to endometrial biopsy as above; do not treat empirically before tissue or imaging data are in hand.
- Complications
Delayed diagnosis of endometrial cancer from deferred workup allows progression from stage I, surgically curable disease to advanced disease with nodal or distant spread.
- Prognosis
Endometrial cancer detected at stage I has a 5-year survival rate of 80% to 90%, reflecting the fact that type I tumors bleed early and are usually caught while confined to the uterus.
- Prevention
Any postmenopausal bleeding must trigger evaluation within the current visit or promptly thereafter, rather than watchful waiting, given the age-related pretest probability of malignancy.
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Endometrial cancer
Endometrial cancer is the most common gynecologic malignancy, most often a type I endometrioid adenocarcinoma driven by unopposed estrogen and heralded by postmenopausal bleeding. Any postmenopausal bleeding or thickened endometrial stripe prompts endometrial biopsy, and early-stage disease is treated with total hysterectomy and bilateral salpingo-oophorectomy, giving a favorable overall prognosis.
- Endometrial polyp
Endometrial polyps are focal, usually benign, estrogen-sensitive overgrowths of endometrial glands and stroma projecting into the uterine cavity that present with abnormal or intermenstrual bleeding; diagnosis is by saline-infusion sonohysterography or hysteroscopy, and treatment is hysteroscopic polypectomy with pathology, which is both diagnostic and curative.
- Evaluation of abnormal uterine bleeding
Abnormal uterine bleeding is any deviation from normal menstrual volume, duration, frequency, or regularity, classified by the PALM-COEIN system into structural and nonstructural causes. Pregnancy is excluded first with beta-hCG, postmenopausal bleeding gets an endometrial biopsy, and acute heavy bleeding is treated first-line with high-dose IV conjugated estrogen.
- Genitourinary syndrome of menopause
Genitourinary syndrome of menopause is the chronic, progressive constellation of vulvovaginal and lower urinary tract symptoms caused by estrogen deficiency, presenting with vaginal dryness, dyspareunia, and recurrent urinary symptoms in menopausal women. It is a clinical diagnosis treated first with nonhormonal moisturizers and lubricants, then low-dose vaginal estrogen, with ospemifene or vaginal prasterone reserved as second-line options.
- Menopause
Menopause is the permanent cessation of menses from ovarian follicular depletion, confirmed retrospectively after 12 months of amenorrhea around a mean age of 51 years. Management centers on treating moderate to severe vasomotor symptoms with the lowest effective dose of hormone therapy in appropriately selected candidates, alongside bone and cardiovascular risk assessment.
- Uterine fibroids
Uterine leiomyomas are benign monoclonal smooth-muscle tumors of the myometrium that cause heavy menstrual bleeding, bulk symptoms, and reproductive dysfunction; management ranges from expectant care to hormonal bleeding control to fertility-sparing or definitive surgery.
- Cervical cancer
Invasive cervical carcinoma is a human papillomavirus-driven squamous or glandular cancer staged by FIGO criteria, treated with fertility-sparing or radical surgery for early disease and cisplatin-based chemoradiation for locally advanced disease.